Loading...
Time from randomization to BICR-assessed radiographic disease progression or death
Time from randomization to death
Time from randomization to investigator-assessed radiographic disease progression or death
Time from randomization to the first BICR-assessed occurrence of disease progression in the central nervous system (CNS)
Proportion of patients with a confirmed intracranial response (intracranial complete response [IC-CR] or intracranial partial response [IC-PR]) among patients with measurable CNS disease at baseline
Time from first intracranial response (IC-CR or IC-PR) to radiographic intracranial disease progression or death
Proportion of patients with a complete response or partial response
Time from first response (complete or partial) to radiographic disease progression or death
Time to investigator-assessed intracranial progression
Incidence and severity of TEAEs and changes in clinically relevant laboratory parameters
Changes in patient-reported outcomes (PROs) assessed by the European Organization for Research and Treatment of Cancer QoL core questionnaire - Cancer (EORTC QLQ-C30)
Changes in PROs assessed by the European Organization for Research and Treatment of Cancer QoL - Lung Cancer module (EORTC QLQ-LC29)
Changes in PROs assessed by the European Quality of Life (EuroQol) 5-dimension questionnaire (EQ-5D-5L)